MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    Understanding the illness experience of people living with Parkinson’s disease: A mixed methods study

    JJ.Y.-Y. Kwok, M.M. AuYeung, H.Y.-L. Chan (Hong Kong, Hong Kong)

    Objective: This study aimed to (i) examine the relationship of psychological distress and HRQoL and (ii) explore the illness experience among people with PD.  Background:…
  • 2017 International Congress

    The FDA is listening: Integrating the voice of the patient in drug development for Parkinson’s and Huntington’s diseases.

    D. Stephenson, A. Porter, K. Romero, G. Podskalny, E. Bastings, B. Dunn, S. Goldstein, T. Mullin (Tucson, AZ, USA)

    Objective: To present highlights from the Patient-Focused Drug Development (PFDD) meetings held at FDA for Parkinson’s disease (PD) and Huntington’s disease (HD) to raise awareness…
  • 2017 International Congress

    Factors that contribute to the greatest levels of caregiver strain in Parkinson’s

    A. Hand, L. Oates, W. Gray, R. Walker (North Shields, United Kingdom)

    Objective: To identify factors that cause the greatest levels of caregiver strain in moderate to advanced Parkinson’s Disease (PD) Background: Many people with PD (PwP)…
  • 2017 International Congress

    Treatment Outcomes for Deep Brain Stimulation in Sex-Linked Dystonia Parkinsonism (XDP, DYT3) Up To 60 Months Follow-up – A Case Series

    J.E. Abejero, J. Aguilar, T. Vesagas, R. Teleg, J. Anlacan, R.D. Jamora (Manila, Philippines)

    Objective: This case series presented the treatment outcomes of the eight (8) XDP patients who underwent DBS in a tertiary hospital and compared it to previous…
  • 2017 International Congress

    Advanced DBS programming – Multiple Groups :  3yrs experience

    g. hosurkar, r. gopalakrishnan (Bengaluru, karnataka, India)

    Objective: To study the utility of multiple programme groups of DBS parameters in the parkinson disease patients following up in our hospital in the last…
  • 2017 International Congress

    Directional distribution of subthalamic nucleus beta activity in patients with Parkinson’s disease

    G. Tinkhauser, A. Pogosyan, I. Debove, A. Nowacki, H. Tan, K. Petermann, K. Seidel, M. Oertel, C. Pollo, P. Brown, M. Schuepbach (Oxford, United Kingdom)

    Objective: To investigate the spatial distribution of subthalamic nucleus (STN) beta activity in Parkinson’s disease (PD) recorded from directional deep brain stimulation (DBS) electrodes.  Background:…
  • 2017 International Congress

    Effects of deep brain stimulation in genetic parkinsonism

    L. Oliveira, R. Cury, E. Barbosa (Sao Paulo, Brazil)

    Objective: The aim of this systematic review is to explore studies on the effects of DBS in genetic parkinsonism. Background: Therapeutic strategies for Parkinson’s disease…
  • 2017 International Congress

    GammaKnife subthalamotomy for Parkinson’s disease

    t. witjas, r. carron, a. eusebio, j.p. azulay, j. regis (marseille, France)

    Objective: To assess the feasibility of GammaKnife subthalamotomy in Parkinson's disease Background: Chronic STN stimulation is an established treatment for complicated PD. Bilateral subthalamotomy may…
  • 2017 International Congress

    Improvement of apraxia of eyelid opening in a patient with Parkinson’s disease following the change of the implantable pulse generator for subthalamic nucleus deep brain stimulation .

    T. Kadowaki, K. Suzuki, E. Hoshiyama, T. Uchiyama, T. Shingo, K. Hirata (Mibu, Japan)

    Objective: To report a patient with Parkinson's disease (PD) in whom apraxia of eyelid opening (ALO) improved after the change of another implantable pulse generator…
  • 2017 International Congress

    Improvements in Clinical Global Impression of Change With Deutetrabenazine Treatment in Tardive Dyskinesia From the ARM-TD and AIM-TD Studies

    H. Fernandez, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, L. Jarskog, J. Jimenez-Shahed, R. Kumar, S. Ochudlo, W. Ondo, K. Anderson (Cleveland, OH, USA)

    Objective: To evaluate the efficacy of deutetrabenazine (DTB), as measured by the Clinical Global Impression of Change (CGIC), in patients with tardive dyskinesia (TD) from…
  • « Previous Page
  • 1
  • …
  • 92
  • 93
  • 94
  • 95
  • 96
  • …
  • 155
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • #23285 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley